GlobeNewswire·Nov 6, 2026, 8:00 AM ET

Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB

Acrivon Therapeutics acquired ACR-525 (formerly AQ280), a Phase 2-ready oral JAK1 inhibitor, & a PKCθ inhibitor preclinical program from Aqilion AB to establish immunology & inflammation as a strategic pillar alongside oncology.
Due diligence utilizing AP3 profiling identified ACR-525 as a highly selective JAK1 inhibitor with minimal off-target effects compared to approved JAK inhibitors & broader cellular effects than dupilumab.
Eosinophilic esophagitis (EoE) is targeted as the first potential indication for ACR-525 using a formulation designed for patients with difficulty swallowing.
The selectivity & oral availability of ACR-525 provide rationale for broad opportunities in Inflammatory Bowel Disease (IBD) & other disorders as a single agent or in combination with PKCθ, IL-23, & TNF inhibitors.
Acrivon plans to use its AP3 platform to identify ACR-525-sensitive disorders, optimize patient selection, & guide dose optimization using PD biomarkers.
The transaction involved an undisclosed cash consideration with no future royalties or milestone obligations & was closed concurrently with the signing of the definitive agreement.
Acrivon, Aqilion, & LEO Pharma entered into an agreement terminating all future royalty & milestone obligations on ACR-525 previously agreed to between Aqilion & LEO Pharma.
The company will host a webcast with key opinion leaders on November 10, 2026, at 4:00 p.m. ET to discuss the ACR-525 & PKCθ inhibitor programs.